Onward Medical Bv Stock EBITDA
| 63E Stock | 4.47 0.09 2.05% |
ONWARD MEDICAL BV fundamentals help investors to digest information that contributes to ONWARD MEDICAL's financial success or failures. It also enables traders to predict the movement of ONWARD Stock. The fundamental analysis module provides a way to measure ONWARD MEDICAL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ONWARD MEDICAL stock.
ONWARD |
ONWARD MEDICAL BV Company EBITDA Analysis
ONWARD MEDICAL's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current ONWARD MEDICAL EBITDA | (33.44 M) |
Most of ONWARD MEDICAL's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ONWARD MEDICAL BV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, ONWARD MEDICAL BV reported earnings before interest,tax, depreciation and amortization of (33.44 Million). This is much lower than that of the sector and significantly lower than that of the Biotechnology industry. The ebitda for all Germany stocks is notably higher than that of the company.
ONWARD EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ONWARD MEDICAL's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ONWARD MEDICAL could also be used in its relative valuation, which is a method of valuing ONWARD MEDICAL by comparing valuation metrics of similar companies.ONWARD MEDICAL is currently under evaluation in ebitda category among its peers.
ONWARD Fundamentals
| Return On Equity | -2.89 | |||
| Return On Asset | -0.34 | |||
| Operating Margin | (19.04) % | |||
| Shares Owned By Insiders | 41.37 % | |||
| Shares Owned By Institutions | 39.43 % | |||
| Revenue | 1.78 M | |||
| Gross Profit | (10.58 M) | |||
| EBITDA | (33.44 M) | |||
| Book Value Per Share | 2.28 X | |||
| Earnings Per Share | (3.62) X | |||
| Number Of Employees | 76 | |||
| Market Capitalization | 34.4 M |
About ONWARD MEDICAL Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ONWARD MEDICAL BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ONWARD MEDICAL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ONWARD MEDICAL BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in ONWARD Stock
ONWARD MEDICAL financial ratios help investors to determine whether ONWARD Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ONWARD with respect to the benefits of owning ONWARD MEDICAL security.